Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00539942 · ClinicalTrials.gov registry record · Phase 3
Study of Arixtra (Fondaparinux Sodium) to Prevent Blood Clots in Women Undergoing Abdominopelvic Surgery for Likely Gynecologic Malignancy
A Phase 3 study, sponsored by University of Alabama at Birmingham.
- Terminated
- Registry status
- Phase 3
- Development phase
- 7
- Enrollment target
NCT00539942 is a Phase 3 study that was terminated before completion, run by University of Alabama at Birmingham. The registered enrollment target is 7 participants.
The verdict
NCT00539942, a Phase 3 study, was terminated before completion, sponsored by University of Alabama at Birmingham.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a randomized trial to compare intermittent compression devices with or without post-operative Arixtra (fondaparinux sodium) in women undergoing major abdominal surgery for known or presumed gynecologic malignancies. This trial seeks to determine if there is a difference in the rate of deep venous thrombosis between these two groups.
Interventions
- DRUG Arixtra (fondaparinux sodium)
- DEVICE Intermittent compression devices (ICD)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2007-04 |
| Est. Completion | 2010-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00539942
The ClinicalTrials.gov registry entry for NCT00539942 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Arixtra (fondaparinux sodium) is the first listed.
NCT00539942 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00539942 about?
NCT00539942 is a clinical study titled "Study of Arixtra (Fondaparinux Sodium) to Prevent Blood Clots in Women Undergoing Abdominopelvic Surgery for Likely Gynecologic Malignancy". This is a randomized trial to compare intermittent compression devices with or without post-operative Arixtra (fondaparinux sodium) in women undergoing major abdominal surgery for known or presumed gynecologic malignancies. This trial seeks to determine if there is a difference in the rate of deep v...
What is the current status of trial NCT00539942?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 7 participants. The study started on 2007-04. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00539942?
The interventions under investigation include: Arixtra (fondaparinux sodium) (DRUG), Intermittent compression devices (ICD) (DEVICE).
Who is sponsoring clinical trial NCT00539942?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.